

REMARKS

Applicants acknowledge with appreciation the indication of allowable subject matter in claims 1-7. The Official Action stated that the claims would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims. However, applicants respectfully submit that claim 1 is already in independent form the base claim.

This application is amended in a manner believed to place it in condition for allowance at the time of the next Official Action.

Claims 1 and 11-13 are amended. Support for the amendment to claim 1 may be found, for example, in NAGUIB and GALAL et al. provided by the Examiner, which disclose the structural formulas for ferutinine and jaeschkeanadiol. Support for the amendment to claims 11-13 may be found generally throughout the specification, for example, in Example 7 on page 10.

Claims 1-7 and 11-13 remain pending in the application.

The present specification has been amended to (1) reflect that the present application is a 371 application, as required by the Official Action, and (2) reflect the correct structural formulas for ferutinine and jaeschkeanadiol as required by the Official Action.

The Official Action rejected claim 1 under 35 USC 112, second paragraph, as being incomplete. Applicants respectfully disagree.

As suggested by the Examiner, claim 1 is amended to correctly recite the structural formulas for ferutinine and jaeschkeanadiol, as recognized by NAGUIB and GALAL et al.

Therefore, applicants respectfully request that the rejection be withdrawn.

Claims 6 and 13 were rejected under 35 USC 112, second paragraph as being indefinite. Applicants respectfully disagree.

Claim 6 was rejected for reciting "[[or 5]]", as this notation was unclear to the Examiner. It is respectfully submitted that double brackets indicate a term is deleted from the claim, as reflected in the currently recited claim 6.

Claim 13 was rejected for reciting "p-pivaloyloxybenzoic". Claim 13 is amended to recite ferutinine, or "p-pivaloyloxyferutinine" (formula IV).

Therefore claims 6 and 13 are definite, and applicants respectfully request that the rejection be withdrawn.

Claims 12 and 13 were rejected under 35 USC 103(a) as being unpatentable over TAMEMOTO et al. (TAMEMOTO). Applicants respectfully disagree.

Applicants respectfully note that claim 11 was not rejected under 35 USC 103(a), but claim 11 is discussed below along with the rejection of claims 12 and 13.

TAMEMOTO was offered for teaching a folk medicine for the treatment of skin diseases and wounds, which comprises ferutinine.

The Official Action stated that it would have been obvious to a person of ordinary skill in the art to make a dermatological composition from the ferutinine taught by TAMEMOTO in combination with an acceptable excipient, as one would have been motivated to optimize the process in order to explore the application to other skin-related diseases.

However, the methods recited in claims 11-13 are directed to preparing cosmetic compositions. Applicants respectfully submit that TAMEMOTO fails to disclose or suggest a possible cosmetic use of ferutinine, as disclosed at page 4, line 27 to page 5, line 3 of the present specification and recited in claims 11-13.

Therefore, TAMEMOTO alone cannot render obvious claims 11-13, and applicants respectfully request that the rejection be withdrawn.


In view of the above, applicants believe that the present application is in condition for allowance at the time of the next Official Action. Allowance and passage to issue on that basis is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any

overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



---

Robert Madsen, Reg. No. 58,543  
745 South 23<sup>rd</sup> Street  
Arlington, VA 22202  
Telephone (703) 521-2297  
Telefax (703) 685-0573  
(703) 979-4709

RAM/fb